Introduction
Crigler-Najjar Syndrome is a rare condition where the body struggles to process bilirubin, a substance from broken-down red blood cells, which leads to jaundice. If not managed, it can cause Kernicterus, which damages the brain. This article breaks down the types, causes, symptoms, and treatments to help understand how to handle this condition.
Overview and historical context
Crigler-Najjar Syndrome is a rare autosomal recessive disorder that impairs bilirubin metabolism, leading to unconjugated hyperbilirubinemia. This condition was first identified in 1952 by paediatricians John Fielding Crigler and Victor Assad Najjar, who described a group of infants with severe jaundice and high levels of unconjugated bilirubin, often resulting in Kernicterus (a form of brain damage due to bilirubin toxicity).1 Bilirubin, an orange-yellow pigment, is a byproduct of red blood cell breakdown, and its accumulation can cause significant health issues if not managed.
The syndrome’s rarity, with an estimated incidence of 0.6 to 1 case per million live births worldwide, underscores the need for awareness and specialised care.4 It affects both males and females equally and can occur across various ethnic groups, though underdiagnosis may occur in resource-limited settings.
Classification and genetic basis
Crigler-Najjar Syndrome is classified into two types based on the severity of enzyme deficiency:
Type I: Characterised by a complete or nearly complete absence of uridine diphosphate-glucuronosyltransferase (UGT1A1) enzyme activity, leading to severe symptoms and a high risk of Kernicterus.
Type II: Involves partial UGT1A1 enzyme activity, resulting in milder symptoms and a lower risk of neurological damage.
The condition is caused by mutations in the UGT1A1 gene, which encodes the enzyme responsible for conjugating bilirubin, making it water-soluble for excretion. In Type I, mutations often involve deletions or missense mutations leading to no enzyme function, while Type II results from point mutations reducing enzyme production.4 This genetic defect follows an autosomal recessive inheritance pattern, meaning both parents must be carriers for a child to be affected, with a 25% chance per pregnancy for two carrier parents.5
Pathophysiology and clinical presentation
Normally, bilirubin is bound to albumin in the blood, but in Crigler-Najjar Syndrome, unbound unconjugated bilirubin can cross the blood-brain barrier, depositing in brain tissues like the basal ganglia and brainstem, leading to Kernicterus.4 This accumulation is particularly dangerous in newborns, where it can cause irreversible neurological damage.
Symptoms vary by type:
Type I: Jaundice appears shortly after birth, with bilirubin levels often exceeding 20 mg/dL, potentially reaching 50 mg/dL. Without treatment, infants risk Kernicterus, presenting with lethargy, poor feeding, hypotonia, high-pitched cry, and progressing to seizures and coma.5
Type II: Jaundice is milder, typically between 6 and 20 mg/dL, and may worsen during illness or stress. Kernicterus is rare but possible at very high levels, such as 40 mg/dL.7
Kernicterus, also known as chronic bilirubin encephalopathy, manifests in two phases:
- Acute Bilirubin Encephalopathy (ABE): Initial symptoms include sleepiness, mild to moderate hypotonia, and a high-pitched cry, progressing to fever, lethargy, irritability, hypertonia, and potentially seizures or coma
- Chronic Bilirubin Encephalopathy (CBE): Becomes apparent within the first year, characterised by choreoathetoid cerebral palsy, sensorineural hearing loss, gaze abnormalities, and enamel hypoplasia, with cognitive function generally unaffected4
Diagnosis and differential considerations
Diagnosis involves measuring serum unconjugated bilirubin levels, with Type I typically above 20 mg/dL and Type II between 6 and 20 mg/dL.6 It’s crucial to exclude other causes of jaundice, such as hemolytic disorders, through blood tests showing no increased hemolysis.
Genetic testing for UGT1A1 mutations confirms the diagnosis, and the phenobarbital test differentiates types: Type II shows a reduction in bilirubin levels with phenobarbital, while Type I does not due to complete enzyme absence.5
Additional diagnostic tools include bile and urine analysis for bilirubin glucuronides, which are absent in Type I.5
Treatment strategies and management
Treatment aims to reduce bilirubin levels and prevent Kernicterus:
Type I: Requires intensive daily phototherapy, using blue light to convert bilirubin into excretable forms, often for 10-12 hours daily. Plasmapheresis may be used in crises to lower bilirubin levels, and liver transplantation is the only curative option, providing a functional UGT1A1 enzyme.8 Recent studies also explore calcium phosphate, orlistat, and heme oxygenase inhibitors for additional management.4
Type II: Managed with phenobarbital, which induces residual enzyme activity, reducing bilirubin levels by at least 25%. Phototherapy may be used during severe hyperbilirubinemia, and some patients require no treatment beyond routine monitoring.5
Preventive measures include prompt treatment of infections and fevers to avoid Kernicterus, and genetic counseling is recommended for families with a history of the syndrome to understand inheritance risks.5
Prognosis and complications
The prognosis varies by type:
Type I: Without treatment, the risk of Kernicterus is high, leading to severe neurological impairment or death in infancy. With phototherapy, patients can survive into adulthood, but the risk persists if treatment is interrupted. Liver transplantation improves prognosis, though it carries surgical and immunosuppressive risks.9
Type II: Generally favourable, with most patients leading normal lives. Kernicterus is rare but can occur during periods of elevated bilirubin, such as illness or fasting.7
Complications include chronic jaundice, cholelithiasis, and liver cirrhosis, possibly from biliary obstruction, drug toxicity, or phototherapy effects.4
Kernicterus remains the most severe, with up to 30% incidence of permanent neurological impairment in Type I, affecting areas like the hippocampus and geniculate bodies.4
Table: comparison of Crigler-Najjar syndrome types
| Aspect | Type I (Severe) | Type II (Milder) |
| Enzyme Activity | Complete or minimal absence of UGT1A1 | Partial UGT1A1 activity (<10% of normal) |
| Bilirubin Levels | Typically >20 mg/dL, up to 50 mg/dL | 6-20 mg/dL |
| Kernicterus Risk | High, up to 30% incidence | Rare, occurs at high levels (e.g., 40 mg/dL) |
| Treatment | Intensive phototherapy, liver transplant | Phenobarbital, occasional phototherapy |
| Prognosis | Poor without treatment, improved with transplant | Generally good, normal life possible |
Ongoing research and future directions
Gene therapy: Recent trials, such as one published in the New England Journal of Medicine, show promise with AAV vectors delivering UGT1A1, reducing bilirubin levels and allowing some patients to discontinue phototherapy.3 Long-term efficacy and safety are under evaluation, with ongoing studies like those by Genethon.3
Enzyme replacement therapy: Aims to provide the missing enzyme directly, though delivery and stability challenges remain.5
Hepatocyte transplantation: Offers temporary relief by transplanting functional liver cells, potentially serving as a bridge to liver transplantation, with ongoing studies to assess long-term viability.5
These advancements, detailed in recent reviews, aim to reduce the burden of daily phototherapy and improve quality of life.3
Epidemiological insights
The syndrome’s rarity, with an incidence of 0.6-1 per million, suggests underdiagnosis, particularly in regions with limited genetic testing access.4 It affects all populations equally, highlighting the need for global awareness and research to address diagnostic gaps.
FAQs
Can Crigler-Najjar Syndrome be detected before birth?
Yes, prenatal genetic testing can identify UGT1A1 mutations in fetuses, using methods like amniocentesis or chorionic villus sampling.
Is phototherapy safe for long-term use in Crigler-Najjar syndrome?
Phototherapy is generally safe but can cause skin irritation or eye damage if not managed properly, requiring regular monitoring by healthcare providers.
Summary
Crigler-Najjar Syndrome, with its potential for severe complications like Kernicterus, requires early diagnosis and lifelong management. Current treatments like phototherapy and liver transplantation are effective but have limitations.
Ongoing research into gene therapy and other novel approaches offers hope for more effective, less invasive solutions, emphasising the importance of continued scientific exploration and patient support.
References
- Crigler JF, Najjar VA. Congenital familial nonhemolytic jaundice with kernicterus. Pediatrics. 1952 Aug;10(2):169–80. Available from: https://pubmed.ncbi.nlm.nih.gov/12983120
- D’Antiga L, Beuers U, Ronzitti G, Brunetti-Pierri N, Baumann U, Di Giorgio A, et al. Gene therapy in patients with the crigler–najjar syndrome. N Engl J Med [Internet]. 2023 Aug 17 [cited 2025 Jun 5];389(7):620–31. Available from: http://www.nejm.org/doi/10.1056/NEJMoa2214084
- Sambati V, Laudisio S, Motta M, Esposito S. Therapeutic options for crigler-najjar syndrome: a scoping review. Int J Mol Sci. 2024 Oct 13;25(20):11006. Available from:
- https://pubmed.ncbi.nlm.nih.gov/39456788
- Bhandari J, Thada PK, Shah M, Yadav D. Crigler-najjar syndrome. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [cited 2025 Jun 5]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK562171/
- Crigler najjar syndrome - symptoms, causes, treatment | nord [Internet]. [cited 2025 Jun 5]. Available from: https://rarediseases.org/rare-diseases/crigler-najjar-syndrome/
- Entry - #218800 - CRIGLER-NAJJAR SYNDROME, TYPE I - OMIM [Internet]. Omim.org. [cited 2025 Jun 5]. Available from: https://omim.org/entry/218800
- Dhawan A, Lawlor MW, Mazariegos GV, McKiernan P, Squires JE, Strauss KA, et al. Disease burden of Crigler-Najjar syndrome: Systematic review and future perspectives. J Gastroenterol Hepatol. 2020 Apr;35(4):530–43. Available from: https://pubmed.ncbi.nlm.nih.gov/31495946/
- Alharbi FA, Al-Shammari NR, Aloqeely KM, Alharbi FA, Al-Shammari NR, Aloqeely KM. Liver transplantation in a child with crigler-najjar syndrome type i: a case report with review of the literature. Cureus [Internet]. 2023 Jul 18 [cited 2025 Jun 5];15(7). Available from: https://www.cureus.com/articles/132993-liver-transplantation-in-a-child-with-crigler-najjar-syndrome-type-i-a-case-report-with-review-of-the-literature
- Blaschke TF, Berk PD, Scharschmidt BF, Guyther JR, Vergalla JM, Waggoner JG. Crigler-najjar syndrome: an unusual course with development of neurologic damage at age eighteen. Pediatr Res [Internet]. 1974 May [cited 2025 Jun 5];8(5):573–90. Available from: https://www.nature.com/articles/pr1974924
- Cacicedo-Hough E. What is kernicterus [Internet]. Klarity Health Library. 2024 [cited 2025 Jun 5]. Available from: https://my.klarity.health/what-is-kernicterus/
- He T, Geng X, Zhu L, Lin X, Wang L. Type II Crigler-Najjar syndrome: a case report and literature review. Front Med [Internet]. 2024 May 9 [cited 2025 Jun 5];11. Available from: https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2024.1354514/full
- Di Dato F, D’Uonno G, Iorio R. Crigler-Najjar syndrome: looking to the future does not make us forget the present. Orphanet Journal of Rare Diseases [Internet]. 2024 Mar 7 [cited 2025 Jun 5];19(1):102. Available from: https://ojrd.biomedcentral.com/articles/10.1186/s13023-024-03108-x

